Aim: To examine the antihypertrophic effect of ginsenoside Rb 1 (Rb 1 ) induced by prostaglandin F 2α (PGF 2α ] i , and promoted ANP, CaN mRNA, and CaN/NFAT 3 /GATA 4 protein expressions, which were inhibited by either Rb 1 in a concentration-dependent manner (50, 100, and 200 µg/mL) or L-arginine (1 mmol/L). N G -nitro-L-arginine-methyl ester, a nitric oxide synthase inhibitor, could abolish the effects of L-arginine, but failed to change the effects of Rb 1 in the experiments above. Conclusion: The present data implicate that Rb 1 attenuates cardiac hypertrophy, the underlying mechanism may be involved in the inhibition of the Ca 2+ -CaN signal transduction pathway.
Introduction
Cardiac hypertrophy is recognized as an adaptive response characterized by the growth of individual cardiomyocytes in size rather than the increase in cell number. Initially beneficial, sustaining cardiac hypertrophy eventually leads to decompensation and results in dilated cardiomyopathy, arrhythmia, fibrotic disease, heart failure, and even sudden death [1] . Furthermore, some studies have indicated that hypertrophy may not be required for a successful adaptation to increased workload [2] . Clinical studies have found that several classes of drugs, including angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, calcium channel blockers [3] [4] [5] , and nitric oxide (NO) [6] could have some beneficial effects in the prevention or treatment of cardiac hypertrophy. However, more studies should be done to provide more therapeutic choices for cardiac hypertrophy.
It has been reported that ginsenosides extracted from the root of the herb Panax ginseng CA. Mey have many pharmacological effects, including increasing the activity of superoxide dismutase [7] and protecting the brain and heart from ischemic and reperfusion injuries [8, 9] . Notably, ginsenoside Rb 1 (Rb 1 ), a major component in ginsenosides, has been shown to elevate the release of NO in rat ventricular myocytes [10] and decrease intracellular free Ca 2+ in cardiac myocytes and other tissues [11] [12] [13] , which indicates that Rb 1 may be a potential drug for anticardiac hypertrophy.
Prostaglandin F 2α (PGF 2α ) has been shown to induce cardiac myocyte hypertrophy in vitro and cardiac growth in vivo and is a good candidate to mediate the growth of cardiac cells [14] . Meanwhile, Ca 2+ signaling has been reported to play a critical role in the development of cardiac hypertrophy induced by various hypertrophic stimuli [15] . The increased intracellular Ca 2+ binds to calmodulin and regulates several downstream effectors, such as calcineurin (CaN), which is a key mediator of cardiac hypertrophy [16, 17] . CaN dephosphorylates the nuclear factor of activated T cells (NFAT), and then later translocates to the nucleus where it acts with other transcription factors (eg GATA 4 ) for the activation of downstream target genes to induce cardiac hypertrophy [18, 19] . A series of studies has shown that the neuroprotective activities and anti-aging function of Rb 1 were related to decreasing intracellular Ca 2+ [11] [12] [13] . However, whether Rb 1 has antihypertrophic effects on cardiac hypertrophy and inhibits the Ca 2+ -CaN signal pathway has not known as yet.
Materials and methods
Primary culture of myocytes Ventricular myocytes from 1-3-d-old rats (Animal Center of Institute of Surgery Research of the Third Military Medical University, Chongqing, China) were prepared and cultured for 48 h in Dulbecco's modified Eagle's medium (DMEM) containing 20% fetal bovine serum and 0.1 mmol/L bromodeoxyuridine (Sigma, St Louis, Missouri, USA) as described previously [20] . The cells were adjusted to 1. Measurement of cardiomyocytic diameters The cardiomyocytes were fixed in 4% polyformaldehyde solution and stained with HE. The diameter of single cells was measured by the BI2000 Imaging Analytic System (Chengdu Taimeng Sci-Tec, Chengdu, China). Five random fields (10−15 cells per field) from each slide were analyzed. The experiments were repeated 3 times. ] i was measured by the method described before [21] . Briefly, the cells ( 1×10 6 ) were incubated in the medium with Fura 2/AM (5 µmol/L; Sigma, St Louis, USA) for 50 min at 37 °C, then washed 3 times with HBSS (D-HBSS plus 1.30 mmol/L CaCl 2 and 0.5 mmol/L MgCl 2 ) containing 0.2% bovine serum albumin by centrifuging at 500×g for 2 min. The fluorescence value from 1 mL cell suspension was measured by a Shimadzu RF-5000 spectrofluorometer (Kyoto, Japan) with dual excitation wavelengths at 340 and 380 nm and emission wavelengths at 510 nm. The RT-PCR analysis of mRNA Total RNA was extracted from the cardiomyocytes by use of an RNeasy mini kit (Qiagen, Valencia, California, USA). RT-PCR was performed with an RT-PCR kit (Promega, San Jose, California, USA) according to the manufacturer's instructions. The nucleotide sequence of the primers were as follows [22, 23] : (i) atrial natriuretic peptide (ANP): sense 5'-GCC CTG AGC GAG CAG ACC GA -3', antisense 5'-CGG AAG CTG TTG CAG CCT A-3'; (ii) CaN: sense 5'-ACT GGC ATG CTC CCC AGC GGA-3', antisense 5'-GTG CCG TTA GTC TCT GAG GCG-3'; and (iii) β-actin: sense 5'-GAC TAC CTC ATG AAG ATC CTG ACC-3', antisense 5'-TGA TCT TCA TGG TGC TAG GAG CC-3'. The predicted products in size were 202, 244, and 423 bp, respectively. These primers were synthesized by Beijing Dingguo Biotech (Beijing, China). The following conditions of the RT-PCR reactions were met: (i) 1 cycle at 48 °C for 45 min, 94 °C for 2 min; (ii) 35 cycles at 94 °C for 30 s, 60 °C for 30 s, and 72 °C for 1 min; and (iii) 72 °C for 7 min. The products were separated by electrophoresis on 1% agarose gel containing ethidium bromide, and photographed. The integral optical density values for each band of ANP, CaN, and β-actin on the gel were assayed by the BI2000 Imaging Analysis System (Chengdu Taimeng Sci-Tec, China). β-actin was used as an internal control for the semiquantitative assay.
Measurement of cardiomyocytic protein contents
Western blotting The protein (30 µg) from cardiomyocytes separated by 10% SDS-PAGE was transferred onto polyvinylidene difluoride nylon membranes. The blots were probed with mouse anti-CaNA-α (1:200 dilution) or anti-NFAT 3 (1:100 dilution) or anti-GATA 4 antibodies (1:100 dilution; (Santa Cruz Biotechnology, Santa Cruz, California, USA), and then with horseradish peroxidase-conjugated goat anti-mouse immunoglobulin G (1:2500 dilution) antibodies. Immunodetection was carried out using the BI2000 Imaging Analysis System.
Statistical analysis All of the data were expressed as mean±SD and analyzed by either ANOVA or Student's ttest with SPSS 11.5 software (SPSS Inc, Chicago, Illinois, USA. Differences were considered statistically significant at P<0.05.
Results
Effects of Rb 1 on PGF 2α -induced cardiomyocyte hypertrophy Light microscopic findings of the cardiomyocytes showed that the cardiomyocytes treated with PGF 2α (100 nmol/L) became swollen and enlarged with undistinguishable borders among the cells ( Figure 1B ) . Rb 1 (200 µg/mL) markedly alleviated the morphological changes induced by PGF 2α ( Figure 1C ). The addition of L-NAME (1 mmol/L) could not antagonize the effect of Rb 1 on the hypertrophic myocyte (data not shown). Table 1 showed that the diameters and protein contents of the cardiomyocytes treated with PGF 2α significantly increased, compared with that of the control (P<0.01). The treatment of Rb 1 with a variety of concentrations (50, 100, and 200 µg/mL) significantly relieved the changes induced by PGF 2α in a concentration-dependent manner (P<0.05). L-arginine (1 mmol/L) also lowered these changes induced by PGF 2 a (P<0.01). L-NAME (1 mmol/L) abolished the effects of L-arginine, but failed to abolish the effects of Rb 1 (200 µg/mL) on the cardiomyocyte diameter and protein content.
There was a low fundamental expression of ANP mRNA in the cardiac myocytes (0.005±0.002, n=3). PGF 2α treatment obviously increased the ANP mRNA expression, which was significantly antagonized by Rb 1 (200 µg/mL) treatment (Figure 2A) . 
Discussion
It has been reported that the morphological changes of cardiomyocyte hypertrophy can be induced in vitro by stimulating cultured neonatal cardiomyocytes with various growth factors and cytokines, such as angiotensin II, endothelin-1, and PGF 2α , which was similar to those induced by pressure or volume load [14, [24] [25] [26] . The characteristic phenotype of hypertrophy following growth factor stimulation includes an increase of cell volume and protein synthesis with an accumulation of contractile proteins, organization of the contractile proteins into sarcomeric units, as well as the re-expression of fetal cardiac genes, including ANP [27] . In this study, the findings from measuring the diameter, protein content, and ANP mRNA expression of the cardiac myocytes suggested that PGF 2α could induce cardiomyocyte hypertrophy resembling that described by Lai et al [14] , and that Rb 1 could significantly decrease the elevated cardiomyocyte volume, protein content, and ANP mRNA expression caused by PGF 2α .
Our ] i effect rather than the NO release may be responsible for the antihypertrophic effects of Rb 1 .
In the past several years, a number of experiments have implicated that the CaN signal transduction pathway may play an important role in the cardiomyocyte hypertrophy process [28] . We have previously reported that cardiac hypertrophy by PGF 2α may be mediated by the CaN signal pathway in rats [29] . In the present paper, the fact that the transcription and expression of CaN, as well as the expression of the CaN downstream factors increased with elevating [Ca 2+ ] i under the stimulation of PGF 2α to the cardiomyocytes, which were blunted by Rb 1 , suggested that the interference of the CaN signaling pathway might be involved in the antihyper-trophic mechanisms of Rb 1 .
L-arginine, an NO donor, was observed to inhibit cardiomyocyte hypertrophy [30] , which could be abolished by L-NAME. Surprisingly, L-NAME had no influence on either the antihypertrophic effect or on the inhibiting [Ca 2+ ] i rise from Rb 1 . The results suggested that the antihypertrophic effect of Rb 1 might be different from L-arginine, but the relationship between the Rb 1 effects and NO still needs much investigation.
In conclusion, our study demonstrates that Rb 1 can alleviate cardiac hypertrophy in vitro, which may be mediated in part by an inhibitive effect on elevated [Ca 2+ ] i due to the inactivation of the CaN transduction pathway. 
